Neuvivo
Biotechnology Research • 
United States • 1-10 Employees
Company overview
| Headquarters | United States |
| Website | |
| Employees | 1-10 |
| Socials |
Key Contact at Neuvivo
Ari Azhir
Chief Executive Officer
Neuvivo Email Formats
Neuvivo uses 1 email format. The most common is {first initial} (e.g., j@neuvivo.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial} | j@neuvivo.com | 100% |
About Neuvivo
Neuvivo is dedicated to creating therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. We have developed a patented macrophage-targeted technology, NP001, that addresses chronic inflammation, a key factor in the progressive loss of motor function in ALS. NP001 has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need. We are working to move this compound toward approval and delivering an effective and safe new treatment for ALS.
Neuvivo revenue & valuation
| Annual revenue | $598,885 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $2,000,000 |
| Total funding | $11,000,000 |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Neuvivo has 2 employees across 2 departments.
Departments
Number of employees
Neuvivo Tech Stack
Discover the technologies and tools that power Neuvivo's digital infrastructure, from frameworks to analytics platforms.
CDN
Video players
Analytics
JavaScript libraries
CDN
Font scripts
JavaScript libraries
Programming languages
Security
Blogs
Analytics
UI frameworks
India
Belgium
Frequently asked questions
4.8
40,000 users
